Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors
{{output}}
Background: Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody... ...
